Literature DB >> 21981313

The number of benign moles excised for each malignant melanoma: the number needed to treat.

S Sidhu1, O Bodger, N Williams, D L Roberts.   

Abstract

BACKGROUND: The ratio of benign moles excised for each malignant melanoma (MM) diagnosed, i.e. the number needed to treat (NNT), may be a useful indicator of diagnostic accuracy and the efficient use of healthcare resources, and may have personal implications for the patient. AIM: To assess the NNT for a group of consultant dermatologists serving a population of 600,000, and to compare this with similar studies from other countries.
METHODS: This was a retrospective analysis of data on pigmented lesions excised over a 5-year period (2005-2009). The lesions were divided into three groups: benign naevi (BN), dysplastic naevi (DN) and MM. The NNT ratio was calculated as (BN + DN + MM)/MM.
RESULTS: In total, 4691 lesions were examined. The overall mean NNT was 6.3, with a range of 4.9-11.3 for each of nine consultant dermatologists. The mean NNT was 7.6 for female and 4.8 for male patients. There were more patients with BN (n = 3534; 75%) than with DN (n = 407; 9%) or MM (n = 750; 16%). The gender representation was similar in the DN and MM groups, but had a disproportionately female bias in the BN group (67% female, 33% male patients). Overall, there were more female patients in all three groups [2962 female patients (63%) and 1729 male patients (37%)].
CONCLUSIONS: The NNT of 6.3 in this study compares favourably with NNT ratios from studies of dermatologists from other countries. This study may encourage other countries and individual doctors to assess their NNT ratios, as it may be an important indicator of the efficient use of resources and the avoidance of unnecessary surgery for patients. © The Author(s). CED
© 2011 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2011        PMID: 21981313     DOI: 10.1111/j.1365-2230.2011.04148.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  14 in total

1.  Impact of in vivo reflectance confocal microscopy on the number needed to treat melanoma in doubtful lesions.

Authors:  I Alarcon; C Carrera; J Palou; L Alos; J Malvehy; S Puig
Journal:  Br J Dermatol       Date:  2014-04       Impact factor: 9.302

2.  Canine olfactory detection of malignant melanoma.

Authors:  Leon Frederick Campbell; Luke Farmery; Susannah Mary Creighton George; Paul B J Farrant
Journal:  BMJ Case Rep       Date:  2013-10-14

3.  Meta-analysis of number needed to treat for diagnosis of melanoma by clinical setting.

Authors:  Amy J Petty; Bradley Ackerson; Reed Garza; Michael Peterson; Beiyu Liu; Cynthia Green; Michelle Pavlis
Journal:  J Am Acad Dermatol       Date:  2020-01-11       Impact factor: 11.527

4.  Fast raster-scan optoacoustic mesoscopy enables assessment of human melanoma microvasculature in vivo.

Authors:  Hailong He; Christine Schönmann; Mathias Schwarz; Benedikt Hindelang; Andrei Berezhnoi; Susanne Annette Steimle-Grauer; Ulf Darsow; Juan Aguirre; Vasilis Ntziachristos
Journal:  Nat Commun       Date:  2022-05-19       Impact factor: 17.694

5.  [Sequential digital dermatoscopic imaging. How much time is required per patient?].

Authors:  L Kofler; M Egger; H Kofler
Journal:  Hautarzt       Date:  2014-05       Impact factor: 0.751

6.  Using the 7-point checklist as a diagnostic aid for pigmented skin lesions in general practice: a diagnostic validation study.

Authors:  Fiona M Walter; A Toby Prevost; Joana Vasconcelos; Per N Hall; Nigel P Burrows; Helen C Morris; Ann Louise Kinmonth; Jon D Emery
Journal:  Br J Gen Pract       Date:  2013-05       Impact factor: 5.386

7.  Melanoma screening: Informing public health policy with quantitative modelling.

Authors:  Stephen Gilmore
Journal:  PLoS One       Date:  2017-09-25       Impact factor: 3.240

8.  Screening for malignant melanoma-a critical assessment in historical perspective.

Authors:  Wolfgang Weyers
Journal:  Dermatol Pract Concept       Date:  2018-04-30

9.  Assessment of Raman Spectroscopy for Reducing Unnecessary Biopsies for Melanoma Screening.

Authors:  Yao Zhang; Austin J Moy; Xu Feng; Hieu T M Nguyen; Katherine R Sebastian; Jason S Reichenberg; Claus O Wilke; Mia K Markey; James W Tunnell
Journal:  Molecules       Date:  2020-06-20       Impact factor: 4.411

10.  Improving clinical diagnosis of early-stage cutaneous melanoma based on Raman spectroscopy.

Authors:  Inês P Santos; Remco van Doorn; Peter J Caspers; Tom C Bakker Schut; Elisa M Barroso; Tamar E C Nijsten; Vincent Noordhoek Hegt; Senada Koljenović; Gerwin J Puppels
Journal:  Br J Cancer       Date:  2018-11-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.